Lilly's US manufacturing commitment passes $50 billion across four new sites

Eli Lilly and Co. announced that its commitments to build and expand U.S. drug manufacturing since 2020 now exceed $50 billion, more than double the $23 billion the company had pledged between 2020 and 2024.^[1] The new spending centers on four additional plants: three dedicated to making active pharmaceutical ingredients, the raw chemical building blocks of drugs, and one that expands Lilly's capacity to produce injectable, or parenteral, medicines.^[1]

Lilly says the buildout is expected to create more than 3,000 permanent jobs in engineering, research, operations and lab work, plus nearly 10,000 construction jobs during the building phase.^[1] The company frames the investment as a way to reduce reliance on manufacturing outside the U.S. and to steady the supply chain for its medicines.^[1] Lilly's earlier domestic projects include new sites in Research Triangle Park and Concord, North Carolina; the LEAP Innovation District campus in Lebanon, Indiana; an expanded Indianapolis manufacturing base; the Lilly Medicine Foundry, also in Lebanon; and a site in Kenosha County, Wisconsin.^[1]

Industry tracking firm Industrial Info Resources reports that GLP-1 drugs are a major driver of this construction wave across the pharmaceutical sector, not just for Lilly.^[2] The firm cites Lilly plans that include more than $13 billion invested in the Lebanon, Indiana campus; a project in Houston, Texas to make small-molecule ingredients for oral GLP-1 drugs still awaiting regulatory approval, widely understood to refer to orforglipron; a Puerto Rico facility expected to begin contributing to oral-dose GLP-1 production in 2029; a $6 billion campus in Huntsville, Alabama tied to orforglipron; and a seven-building campus in Fogelsville, Pennsylvania linked to Zepbound, Mounjaro, and the experimental drug retatrutide.^[2] Competitor Novo Nordisk is separately investing $4.1 billion to roughly double its square footage at its Clayton, North Carolina campus, which supports Ozempic and Wegovy production, after completing a $2 billion API expansion there in 2020, and it acquired manufacturer Catalent for $11 billion in 2024 to gain additional fill-finish plants.^[2]

The same report notes that GLP-1 use has grown quickly in the U.S. A Gallup poll published in July found 11% of U.S. adults were taking a GLP-1 drug for weight loss in 2026, up from 3% in 2024, with 15% saying they had used one at some point.^[2] A Cornell University-led study found households with at least one GLP-1 user saw grocery bills fall by 6% within six months of starting the drug.^[2]

Why it matters for patients

More domestic manufacturing capacity, especially for active ingredients that are often made overseas, could make it harder for supply disruptions abroad to affect U.S. drug availability, according to Lilly's stated rationale.^[1] New plants tied to orforglipron and to injectable drugs like Zepbound and Mounjaro suggest the company expects continued demand growth for both pill and injection forms of GLP-1 medicines.^[2] None of the sources say whether this spending will change U.S. list prices, insurance coverage, or how quickly shortages of specific doses might ease. The Puerto Rico oral-dose site is not expected to contribute to production until 2029, so any supply benefit from that facility is years away.^[2]

What happens next

The Puerto Rico facility for oral-dose GLP-1 production is projected to come online in 2029.^[2] Timelines for the four newly announced U.S. sites, and for the Houston and Huntsville, Alabama projects tied to orforglipron, were not detailed in the available sources. Orforglipron itself is described as still awaiting regulatory authorization.^[2]